2024
DOI: 10.1021/acsnano.3c10109
|View full text |Cite
|
Sign up to set email alerts
|

mRNA-Laden Lipid-Nanoparticle-Enabled in Situ CAR-Macrophage Engineering for the Eradication of Multidrug-Resistant Bacteria in a Sepsis Mouse Model

Chunwei Tang,
Weiqiang Jing,
Kun Han
et al.

Abstract: Sepsis, which is the most severe clinical manifestation of acute infection and has a mortality rate higher than that of cancer, represents a significant global public health burden. Persistent methicillin-resistant Staphylococcus aureus (MRSA) infection and further host immune paralysis are the leading causes of sepsisassociated death, but limited clinical interventions that target sepsis have failed to effectively restore immune homeostasis to enable complete eradication of MRSA. To restimulate anti-MRSA inna… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
1
0

Year Published

2024
2024
2025
2025

Publication Types

Select...
4
1
1

Relationship

0
6

Authors

Journals

citations
Cited by 13 publications
(1 citation statement)
references
References 62 publications
0
1
0
Order By: Relevance
“…Recently, in vivo delivery of CAR-encoding mRNAs to T cells or macrophages has been used to produce in vivo CAR-T or CAR-macrophage 7-11 . This innovative approach has shown efficacy in treating hematologic malignancies and myocarditis in mouse models, offering an off-the-shelf immunotherapy strategy with immense potential for therapeutic applications [7][8][9][10][11] . The use of mRNA technology addresses the safety concern of genomic integration and enables broader and more accessible application of CAR-T therapy in diverse clinical scenarios.Unlike the linear conformation of mRNA, circular RNAs (circRNAs) are covalently closed circular RNA molecules that are more stable than linear mRNAs in mammalian cells [12][13][14] .…”
mentioning
confidence: 99%
“…Recently, in vivo delivery of CAR-encoding mRNAs to T cells or macrophages has been used to produce in vivo CAR-T or CAR-macrophage 7-11 . This innovative approach has shown efficacy in treating hematologic malignancies and myocarditis in mouse models, offering an off-the-shelf immunotherapy strategy with immense potential for therapeutic applications [7][8][9][10][11] . The use of mRNA technology addresses the safety concern of genomic integration and enables broader and more accessible application of CAR-T therapy in diverse clinical scenarios.Unlike the linear conformation of mRNA, circular RNAs (circRNAs) are covalently closed circular RNA molecules that are more stable than linear mRNAs in mammalian cells [12][13][14] .…”
mentioning
confidence: 99%